Locally Activated Biologics for Selective Treatment of Chronic Sinonasal Inflammation

Abstract

Chronic sinonasal inflammation encompasses a spectrum of disorders, predominantly chronic rhinosinusitis (CRS), characterized by persistent mucosal inflammation and significant morbidity. Traditional systemic therapies often carry risks of adverse effects and limited efficacy in refractory cases. Locally activated biologics have emerged as a promising targeted therapeutic strategy, allowing for site-specific immunomodulation while minimizing systemic exposure. This review explores the epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic approaches, and current management of chronic sinonasal inflammation, with a special focus on the development and clinical integration of locally activated biologics. We summarize recent advances, discuss guideline recommendations, and provide insights into the future of precision-based care in sinonasal disease.

Introduction

Chronic sinonasal inflammation, primarily manifesting as chronic rhinosinusitis with or without nasal polyposis (CRSwNP/CRSsNP), affects a substantial proportion of the global population and exerts a considerable impact on quality of life, healthcare resource utilization, and productivity. The multifactorial etiology, variable clinical phenotypes, and complex immunopathology of these conditions present ongoing challenges in management. Recent advances in molecular biology and immunology have paved the way for biologic therapies targeting specific inflammatory pathways. The advent of locally activated biologics, designed to exert their effects directly at the site of disease, represents a paradigm shift towards more individualized and effective therapies with reduced systemic complications. This review aims to provide a comprehensive, evidence-based analysis for clinicians seeking to optimize care for patients with chronic sinonasal inflammation.

Epidemiology / Disease Burden

Chronic rhinosinusitis is estimated to affect 10-12% of adults globally, with substantial variations across geographic regions and populations. The disease imposes a significant burden, accounting for millions of outpatient visits annually and contributing to direct and indirect economic costs. The prevalence of CRSwNP is lower than CRSsNP but is associated with greater symptom severity, increased risk of comorbid asthma, and higher rates of surgical intervention. Disease chronicity, high recurrence rates, and suboptimal response to conventional therapies emphasize the need for novel approaches to disease management.

Pathophysiology

Chronic sinonasal inflammation arises from a complex interplay of host, environmental, and microbial factors. Key mechanisms include dysregulated innate and adaptive immune responses, epithelial barrier dysfunction, and persistent microbial colonization. In CRSwNP, a Type 2 (Th2) inflammatory response predominates, characterized by elevated interleukin (IL)-4, IL-5, and IL-13, eosinophilia, and local IgE production. Conversely, CRSsNP is often associated with a neutrophil-dominant, Type 1/Type 3 cytokine milieu. These immunologic endotypes underpin the rationale for targeted therapies, including biologics that inhibit specific cytokines or cell surface receptors. Locally activated biologics are engineered to become biologically active only within the inflamed mucosa, enabling precise modulation of disease-driving pathways while sparing healthy tissues.

Risk Factors

Risk factors for chronic sinonasal inflammation include genetic predisposition, atopy, asthma, allergic rhinitis, environmental exposures (pollutants, tobacco smoke), occupational hazards, and impaired mucociliary clearance. Comorbid disorders such as aspirin-exacerbated respiratory disease (AERD) and cystic fibrosis further increase disease complexity and therapeutic challenges. An understanding of patient-specific risk profiles facilitates risk stratification and personalized management, particularly when considering advanced therapies such as biologics.

Clinical Features

Patients typically present with persistent nasal obstruction, mucopurulent drainage, facial pain or pressure, and olfactory dysfunction lasting 12 weeks or more. Endoscopic examination may reveal edematous mucosa, polyps, or purulent secretions, while imaging studies (CT, MRI) elucidate extent of disease and anatomical variations. Symptom severity is best assessed using validated patient-reported outcome measures such as the Sino-Nasal Outcome Test (SNOT-22). Chronicity and recurrence, despite optimal medical and surgical management, are hallmarks of severe disease and candidates for advanced therapies.

Diagnosis

Diagnosis relies on a combination of clinical evaluation, nasal endoscopy, and imaging. The presence of characteristic symptoms, objective findings of mucosal inflammation, and exclusion of alternative causes underpin the diagnostic criteria. Tissue biopsies and molecular assays may aid in differentiating endotypes and guiding targeted therapy. Emerging biomarkers, including peripheral and tissue eosinophil counts and specific cytokine profiles, are increasingly utilized to identify candidates for biologic therapy and monitor treatment response.

Treatment & Management

Conventional management consists of intranasal corticosteroids, saline irrigation, short courses of systemic corticosteroids, and antibiotics for acute exacerbations. Functional endoscopic sinus surgery (FESS) is indicated for refractory cases. However, a subset of patients demonstrates persistent or recurrent disease, highlighting the need for adjunctive therapies. Systemic biologics, such as anti-IL-5, anti-IL-4R, and anti-IgE monoclonal antibodies, have demonstrated efficacy in severe CRSwNP but are limited by cost, accessibility, and potential systemic side effects. Locally delivered and locally activated biologics are being developed to address these limitations, offering sustained, potent anti-inflammatory effects at the site of pathology with reduced systemic exposure.

Recent Advances / Emerging Therapies

Locally activated biologics represent a novel class of therapeutics that leverage prodrug strategies, controlled-release formulations, and site-specific activation (e.g., via protease-sensitive linkers) to achieve selective action within diseased sinonasal tissues. Early-phase clinical trials have demonstrated promising efficacy, with reduced polyp size, improved symptom scores, and favorable safety profiles. For example, topical delivery of monoclonal antibodies via nasal sprays, drug-eluting stents, or biodegradable gels enables high local concentrations and prolonged mucosal contact. Preclinical studies are exploring gene-editing approaches and nano-carriers for targeted cytokine blockade. As these therapies progress through clinical development, their integration into current treatment algorithms holds promise for truly personalized medicine in sinonasal disease.

Guideline Recommendations

Current international and national guidelines advocate for a stepwise approach to CRS management, emphasizing optimal medical therapy and judicious use of surgery. Biologics are recommended for patients with severe, refractory CRSwNP, particularly those with comorbid asthma or AERD. While most evidence to date pertains to systemic biologics, evolving data on locally activated biologics are anticipated to inform future revisions of consensus guidelines. Clinicians should remain abreast of emerging evidence, consider patient selection carefully, and balance efficacy with safety and cost-effectiveness when integrating advanced therapies into practice.

Conclusion

The advent of locally activated biologics represents a significant advancement in the selective treatment of chronic sinonasal inflammation. By enabling precise, site-specific modulation of key inflammatory pathways, these therapies offer the potential for enhanced efficacy and improved safety profiles compared to conventional systemic interventions. Ongoing research and clinical trials will determine their ultimate place in therapy, but current evidence supports their promise as a component of personalized, guideline-driven care for chronic rhinosinusitis and related disorders. Continued collaboration between clinicians, researchers, and industry will be essential to optimize outcomes and realize the full potential of these innovative therapies.